About Heptares | Company
Heptares is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. We are an industry pioneer in GPCR structure-based drug design (SBDD) and have built a powerful and unique capability for discovering both small molecule and antibody medicines targeting GPCRs. Our SBDD platform enables us to unlock GPCRs that have strong clinical and biological validation, yet which have proven to be historically hard to drug
Using this approach, we have generated an exciting pipeline of new medicines with potential to transform the treatment of a wide range of human diseases. Our pipeline of potential first-in-class and best-in-class candidates is diversified across neuroscience, immuno-oncology, metabolic and orphan disease areas, creating a rich and sustainable set of possibilities for partnering and for internal development and commercialisation.
Our current partners for our Pipeline programmes include world-leading pharmaceutical companies such as Allergan, AstraZeneca, MedImmune and Teva. In addition, we have a strategic collaboration with Kymab focused on the joint discovery, development and commercialisation of novel antibody therapeutics aimed at immuno-oncology targets.
In parallel to building our own pipeline of molecules engineered de novo, we have signed multiple Technology alliances, which leverages our SBDD product engine to identify novel small molecule and antibody therapeutics targeting GPCRs of strategic interest to large and specialty pharma companies, including AstraZeneca, MedImmune, MorphoSys and Pfizer.
Heptares was founded in 2007 to develop and commercialise pioneering research from the MRC Laboratory of Molecular Biology (LMB; Cambridge, UK) and the National Institute of Medical Research (London, UK). We retain an active collaboration with LMB and have rights to all IP generated there relating to the application of the technology to GPCRs and other transmembrane proteins. In 2016, Heptares gained additional complementary GPCR stabilisation technologies and expertise through its acquisition of G7 Therapeutics (renamed Heptares Therapeutics Zurich).
Heptares is a wholly owned subsidiary of Sosei Group Corporation.
The origin of the name Heptares is the Greek for the number seven ('hepta'), which in this case refers to the seven transmembrane helices that are a common structural feature of all GPCRs.